FTXH — First Trust Nasdaq Pharmaceuticals ETF
Data updated: 2026-06-10
FTXH — First Trust Nasdaq Pharmaceuticals ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $29.18M AUM · 0.60% expense ratio · 26.5% 1-yr return. From SEC regulatory filings.
FTXH Fund Overview
FTXH — First Trust Nasdaq Pharmaceuticals ETF is a US ETF managed by First Trust Exchange-Traded Fund VI, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: First Trust Exchange-Traded Fund VI
- Category: United States Health Care Equity
- Assets under management: $29.18M
- 1-year return: 26.5%
- Ticker: FTXH
- SEC CIK: 0001552740
- SEC series ID: S000053945
- Share class ID: C000169747
FTXH Holdings
Top 10 holdings of First Trust Nasdaq Pharmaceuticals ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Johnson & Johnson | 7.45% |
| Bristol-Myers Squibb Company | 7.36% |
| Merck & Co., Inc | 7.36% |
| AbbVie Inc. | 7.10% |
| Eli Lilly & Co. | 6.62% |
| Pfizer Inc. | 3.85% |
| Regeneron Pharmaceuticals, Inc. | 3.74% |
| Biogen Inc | 3.62% |
| Gilead Sciences Inc. | 3.54% |
| Cardinal Health, Inc. | 3.49% |
FTXH Portfolio Allocation
Asset-class allocation of First Trust Nasdaq Pharmaceuticals ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.9% |
| Cash & Equivalents | 0.1% |
FTXH Performance
Total returns for FTXH (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 4.4% |
| 1 year | 26.5% |
| 3 years (annualised) | 11.2% |
| 5 years (annualised) | 7.6% |
FTXH Risk Information
Risk metrics for FTXH, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 15.8%
FTXH Costs and Fees
FTXH costs about $60 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.60%
- Gross expense ratio: 0.60%
- Portfolio turnover: 28%
- Brokerage commissions: 1.40 bps of average net assets (SEC N-CEN)
FTXH Cashflows
Over the 12 months to 2026-03, First Trust Nasdaq Pharmaceuticals ETF had net inflows of $9.78M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-03 | $0 |
| 2026-02 | $5.25M |
| 2026-01 | $1.69M |
| 2025-12 | $1.67M |
| 2025-11 | $0 |
| 2025-10 | $1.46M |
FTXH Debt Constituents
No individual debt constituents are reported in First Trust Nasdaq Pharmaceuticals ETF's latest SEC N-PORT filing.
FTXH Prospectus and SEC Filings
Official First Trust Nasdaq Pharmaceuticals ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.